- Home
- LIVN vs IRON Comparison
LIVN vs IRON Comparison
Compare LIVN & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LIVN | IRON |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.4B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | LIVN | IRON |
|---|---|---|
| Price | $63.43 | $80.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $65.00 | ★ $108.85 |
| AVG Volume (30 Days) | 629.9K | ★ 684.8K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,348,962,000.00 | N/A |
| Revenue This Year | $12.25 | N/A |
| Revenue Next Year | $6.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.63 | N/A |
| 52 Week Low | $32.48 | $30.82 |
| 52 Week High | $65.57 | $99.50 |
Technical Indicators
Market Signals| Indicator | LIVN | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 61.02 | 34.31 |
| Support Level | $61.79 | $71.41 |
| Resistance Level | $64.00 | $92.00 |
| Average True Range (ATR) | 1.44 | 4.59 |
| MACD | -0.35 | -1.88 |
| Stochastic Oscillator | 38.85 | 31.00 |
Price Performance
Historical ComparisonAbout LIVN LivaNova PLC
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.